A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib

Conditions: Non Small Cell Lung Cancer Metastatic; ALK Gene Mutation Interventions: Drug: Lorlatinib Sponsors: Centro di Riferimento Oncologico - Aviano Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials